Amgen Inc (AMGN) Receives a Hold from RBC Capital

By Carrie Williams

RBC Capital analyst Kennen MacKay maintained a Hold rating on Amgen Inc (AMGNResearch Report) today and set a price target of $192. The company’s shares opened today at $169.69, close to its 52-week low of $166.30.

According to TipRanks.com, MacKay is a 5-star analyst with an average return of 13.4% and a 53.9% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Aimmune Therapeutics, and Akebia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $210.30 average price target, a 23.9% upside from current levels. In a report issued on May 14, J.P. Morgan also maintained a Hold rating on the stock with a $190 price target.

See today’s analyst top recommended stocks >>

Based on Amgen Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.54 billion and net profit of $1.99 billion. In comparison, last year the company earned revenue of $5.59 billion and had a net profit of $2.31 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.